Ebola Isn’t One Virus. We’ve Been Treating It Like One.

By Jared Bauer, CEO

Ebola Bundibugyo (BDBV) is the strain driving the current outbreak in the Democratic Republic of the Congo and Uganda — and it is one the world is dangerously unprepared for.

“No vaccine exists. No therapy exists. The virus circulated undetected for six weeks. Cross-border spread is confirmed. Every day without a fully resourced response is a day the outbreak gains ground.”

That is not a worst-case projection. It is a summary from a WHO Africa team presentation on the current Ebola outbreak in the Democratic Republic of the Congo and Uganda, now declared a Public Health Emergency of International Concern. Leading epidemiologists describe it as moving at “breakneck speed” through a region destabilized by insecurity and population displacement.

That is what it looks like when we face a known disease with no vaccine, no approved treatment, and no reliable diagnostic. The disease in question is Ebola Bundibugyo — and it is not the Ebola most people know.

Ebola Bundibugyo Is Not Like Other Strains

Most people don’t realize this: Ebola is not one virus. It is a family of six distinct species, and the vaccines and therapeutics developed over the last decade were built for only one of them: Zaire. The current outbreak is driven by Ebola Bundibugyo — formally known as Bundibugyo ebolavirus (BDBV). The Zaire vaccine doesn’t work for it, there is no approved therapeutic, and the standard rapid tests most public health systems rely on cannot reliably detect it. In fact, the WHO explicitly advises against depending on them for this strain.

For most of the history of outbreak response, developing countermeasures required years of species-specific research. The scientific capability to work across a viral family simultaneously, analyzing multiple species in parallel, identifying shared vulnerabilities, and designing therapeutics that target them, simply did not exist. The gap in our Bundibugyo preparedness reflects that constraint.

That constraint has changed. The convergence of genomic sequencing, AI-enabled analysis, and programmable therapeutic platforms now makes it possible to decode pathogens at the sequence level, across species and across families, before an outbreak forces the work to begin. What was once a sequential, reactive process can now be a parallel, proactive one.

Responding to Ebola at the Sequence Level

When our team applied BioSeeker, our AI-powered discovery engine, to the current Bundibugyo sequences, what we found was enlightening.

The 2026 BDBV sequences are approximately 98% similar to those from the original 2007 outbreak. This is not a rapidly mutating novel pathogen. It is a known virus on a known genetic trajectory, and that stability is precisely what makes it a strong candidate for sequence-directed therapeutic design. Conserved regions identified today are likely to remain relevant across future outbreaks.

Within the Bundibugyo genome, our platform identified conserved, functionally essential regions: parts of the virus that remain stable across strains because they are structurally critical to how it replicates. A virus can mutate around many targets, but it cannot easily mutate around the machinery it requires to function. These conserved regions are the basis for a CRISPR-based therapeutic approach: sequence-directed intervention designed to cut the viral genome and stop replication. Critically, this approach is programmable: as new sequence data emerges, the therapeutic can be updated. It is not frozen at the moment of development the way a traditional vaccine is.

No therapeutic candidate has been advanced based on this work; development would require a full clinical process. But the starting point is different. Instead of beginning from zero when a PHEIC is declared, we already have a decoded map of where the virus is vulnerable and a therapeutic modality designed to act on it.

We Have to be Ready for the Next Outbreak

The deeper implication is not just speed. It is parallelization. The reactive model forces triage: resources concentrate on the active outbreak while every other known threat waits.

Bundibugyo is not an anomaly. Across the Ebola family and beyond, the same challenge recurs: known pathogens, sequenced genomes, and no approved vaccines or treatments because the outbreak that would have triggered development hasn’t arrived yet.
We know which pathogen families pose the greatest risk. We can see the gaps. The question is whether we build ahead of them or wait to react.